Literature DB >> 11462931

Activation of blood platelets in chronic hepatitis and liver cirrhosis P-selectin expression on blood platelets and secretory activity of beta-thromboglobulin and platelet factor-4.

A Panasiuk1, D Prokopowicz, J Zak, J Matowicka-Karna, J Osada, J Wysocka.   

Abstract

BACKGROUND/AIMS: Blood platelets are cells that quite often undergo damage in chronic liver diseases. Endotoxemia and hyperkinetic circulation influence platelets in an active manner. The role of platelets in the development of hepatitis and liver fibrosis is speculative. The aim of the study was to determine the influence of chronic liver diseases on platelets morphologic parameters, their secretory activity and P-selectin expression.
METHODOLOGY: The examination was completed in the group of 29 patients with chronic hepatitis and 27 with liver cirrhosis of postinflammatory etiology (HBV, HCV). Liver biopsies were carried out in all patients. Thirty-two healthy individuals were the control group. Platelets morphological parameters (number, volume, platelet crit, micro- and macrothrombocyte fraction) were estimated. beta-thromboglobulin concentration and platelet factor 4 in blood serum as well as P-selectin expression on resting platelets and after thrombin activation were also examined.
RESULTS: Number, volume, and platelet crit decreased with the advancement of a liver disease. Megathrombocyte fraction increased inversely with the severity of liver damage. The concentration of beta-thromboglobulin and platelet factor 4 alpha-granule contents in blood serum was higher 2- and 7-times, respectively than in healthy controls. P-selectin expression on resting platelets was considerably higher. After stimulation with thrombin, P-selectin expression was equal (chronic hepatitis) or higher (liver cirrhosis) than in the control.
CONCLUSIONS: There are changes of platelet morphological parameters, with accompanying megathrombocyte fraction increase that occur in chronic liver diseases. Thrombocytes in chronic liver diseases and liver cirrhosis are more activated. Platelet sensitivity to stimuli in these ailments is higher (liver cirrhosis) than in the healthy controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11462931

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  19 in total

1.  Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis.

Authors:  Anatol Panasiuk; Jolanta Wysocka; Elzbieta Maciorkowska; Bozena Panasiuk; Danuta Prokopowicz; Janusz Zak; Karol Radomski
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

2.  Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation.

Authors:  Karl Egan; Audrey Dillon; Eimear Dunne; Barry Kevane; Zita Galvin; Patricia Maguire; Dermot Kenny; Stephen Stewart; Fionnuala Ni Ainle
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

3.  Assessing in vivo platelet activation in patients with liver diseases.

Authors:  Ton Lisman
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

4.  Immune Activation of Platelets in Response to Serial Phlebotomy in Pigtailed Macaques (Macaca nemestrina).

Authors:  Meghan S Vermillion; Claire E Lyons; Kevin M Najarro; Robert J Adams; Kelly A Metcalf Pate
Journal:  Comp Med       Date:  2017-08-01       Impact factor: 0.982

5.  Monocyte chemotactic protein-1 and soluble adhesion molecules as possible prognostic markers of the efficacy of antiviral treatment in chronic hepatitis C.

Authors:  Anatol Panasiuk; Danuta Prokopowicz; Bozena Panasiuk
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

Review 6.  Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Onán Pérez-Hernández; Lucía Romero-Acevedo; Francisco Santolaria-Fernández
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

7.  Risk Factors for Transfusion after Orthotopic Liver Transplantation.

Authors:  Ana Paula Hitomi Yokoyama; José Mauro Kutner; Araci Massami Sakashita; Cristiane Yoshie Nakazawa; Tatiana Almeida Omura de Paula; Raffael Perreira Cezar Zamper; Pamella Tung Pedroso; Marcio Dias de Almeida; Sergio Paiva Meira Filho; Fernanda Andrade Orsi
Journal:  Transfus Med Hemother       Date:  2019-04-03       Impact factor: 3.747

Review 8.  Targeting von Willebrand factor in liver diseases: A novel therapeutic strategy?

Authors:  Dafna J Groeneveld; Lauren G Poole; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2021-05-03       Impact factor: 16.036

9.  CD62P (P-selectin) expression as a platelet activation marker in patients with liver cirrhosis with and without cholestasis.

Authors:  Sara Hegazy; Maha Elsabaawy; Mohamed Eltabakh; Reham Hammad; Hanan Bedair
Journal:  Clin Exp Hepatol       Date:  2021-06-30

10.  Overview of platelet physiology: its hemostatic and nonhemostatic role in disease pathogenesis.

Authors:  Kakali Ghoshal; Maitree Bhattacharyya
Journal:  ScientificWorldJournal       Date:  2014-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.